Oncology | New Developments | UNITED STATES

Pfizer Inc

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Contact Supplier

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

IDEAYA and Pfizer Enter Clinical Trial Collaboration and Supply Agreement

Lead Product(s): IDE196,Binimetinib

Therapeutic Area: Oncology

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Ideaya Biosciences

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration March 18, 2020

Details:

IDEAYA and Pfizer will form a Joint Development Committee (JDC), and there will be joint decision making and data sharing of the clinical trial results between the parties.

Eagle Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Eagle Pharmaceuticals Advances Novel and Proprietary Formulation of Fulvestrant Product Candidate EA-114

Lead Product(s): Fulvestrant

Therapeutic Area: Oncology

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 04, 2020

Details:

Eagle has obtained additional data on its pilot clinical study of its product candidate, EA-114, which has the potential to enhance estrogen receptor inhibition and improve patient outcomes.

Accent Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Accent Therapeutics nabs $63M for RNA cancer push

Lead Product(s): METTL3

Therapeutic Area: Oncology

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: EcoR1 Capital

Deal Size: $63.0 million Upfront Cash: Undisclosed

Deal Type: Series B Financing April 23, 2020

Details:

Proceeds from the financing will be used to advance the development of Accent’s novel therapies targeting RNA-modifying proteins (RMPs), including its lead programs METTL3 and ADAR1.

Merck & Co. Inc.

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Cue Biopharma Announces Clinical Trial Collaboration Agreement with Merck to Evaluate CUE-101 in Combination with KEYTRUDA

Lead Product(s): CUE-101,Pembrolizumab

Therapeutic Area: Oncology

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Cue Biopharma

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration April 20, 2020

Details:

Under the terms of the agreement, Cue Biopharma will conduct a Phase 1 study, KEYNOTE-A78, evaluating CUE-101 in combination with KEYTRUDA in first-line HPV+ advanced head and neck cancer.

Regeneron Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Zai Lab Targets Blood Cancers In Deal With Regeneron

Lead Product(s): REGN1979

Therapeutic Area: Oncology

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Zai Lab

Deal Size: $190.0 million Upfront Cash: $30.0 million

Deal Type: Licensing Agreement April 08, 2020

Details:

Zai Lab obtains rights to develop and exclusively commercialize REGN1979 in oncology in mainland China, Hong Kong, Taiwan and Macau.

Ultragenyx Pharmaceutical

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Ultragenyx Enters into Strategic Partnership with Daiichi Sankyo for Gene Therapy Manufacturing Technology

Lead Product(s): AAV-based gene therapy

Therapeutic Area: Oncology

Highest Development Status: Undisclosed Product Type: Gene therapy

Partner/Sponsor/Collaborator: Daiichi Sankyo Co Ltd

Deal Size: $225.0 million Upfront Cash: $200.0 million

Deal Type: Licensing Agreement April 01, 2020

Details:

Ultragenyx granted Daiichi Sankyo license to intellectual property, including know-how and patent applications, with respect to its HeLa manufacturing platform for AAV-based gene therapy products.

ElevateBio

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

ElevateBio Closes $170 Million Series B Financing

Lead Product(s): Cell and gene therapy

Therapeutic Area: Oncology

Highest Development Status: Undisclosed Product Type: Gene therapy

Partner/Sponsor/Collaborator: The Invus Group

Deal Size: $170.0 million Upfront Cash: Undisclosed

Deal Type: Series B Financing March 30, 2020

Details:

The financing will support advancement of clinical development with at least six cell and gene therapies from across ElevateBio's portfolio companies to enter clinical studies this year and into 2021.

iBio

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

iBio Supporting AzarGen Biotechnologies’ Development of a Rituximab Biosimilar

Lead Product(s): Rituximab

Therapeutic Area: Oncology

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: AzarGen Biotechnologies

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement March 26, 2020

Details:

iBio plans to transfer its proprietary FastPharming Manufacturing System™ to AzarGen in South Africa for production of critical biological medicines for the African continent.